At Brain+, we care about people affected by dementia. We also care about our shareholders, and it is important for us to provide open and transparent information about our business as we work towards achieving our mission.

We are pioneers in the development of digital Cognitive Stimulation Therapy (CST), the global standard for non-drug treatment of people with dementia. Based on our expertise in software-based training tools, our deep understanding of brain functioning, and a strong network of partnerships in the dementia space, we are building Ayla, the world’s first scalable dementia care platform.

Our first product, Ayla – your CST assistant is certified as medical device in the United Kingdom and available for sale in the United Kingdom and Denmark.